Humanized murine anti-TNF mAb (infliximab) and soluble TNF receptor linked to human IgG1 (etanercept) have been developed and preliminary clinical studies in asthma did show significant improvements in lung function, airway hypereactivity and exacerbation rate, particularly in patients with severe asthma refractory to GC treatment (Brightling et al., 2008). The gene discussed is TNF; the disease is asthma.